Spinal Muscular Atrophy (SMA) Market Treatment, Causes, Size, Pipeline Review, H1 2016

Spinal Muscular Atrophy (SMA) Market Treatment,
Statistics, Share, Pipeline Review, H1 2016
Summary
Global Markets Direct's, 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2016', provides an
overview of the Spinal Muscular Atrophy (SMA) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Spinal
Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and development history and latest
news and press releases. Additionally, the report provides an overview of key players involved in
therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued
projects.
Click for Report Details @ http://www.radiantinsights.com/research/spinal-muscular-atrophy-smapipeline-review-h1-2016
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Direct's proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic
review following a stringent set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective counter strategies to gain
competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance
of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (SMA)
- The report reviews pipeline therapeutics for Spinal Muscular Atrophy (SMA) by companies and
universities/research institutes based on information derived from company and industry-specific
sources
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product
description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental
activities
- The report reviews key players involved Spinal Muscular Atrophy (SMA) therapeutics and enlists all
their major and minor projects
- The report assesses Spinal Muscular Atrophy (SMA) therapeutics based on drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (SMA)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D
strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Spinal
Muscular Atrophy (SMA)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline
therapeutics
- Devise corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA)
pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors
that drove them from pipeline
Browse More Market Research Reports @ http://www.radiantinsights.com/catalog/market-researchreports
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 10
Therapeutics Development 11
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 11
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis 12
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies 13
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by
Universities/Institutes 15
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies 18
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes
20
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development 21
A1M Pharma AB 21
Adrenomed AG 22
Am-Pharma B.V. 23
Angion Biomedica Corp. 24
Atox Bio Inc. 25
Cellmid Limited 26
Complexa, Inc. 27
DiaMedica Inc. 28
Digna Biotech, S.L. 29
DURECT Corporation 30
F. Hoffmann-La Roche Ltd. 31
G1 Therapeutics, Inc. 32
Ischemix, Inc. 33
Kringle Pharma, Inc. 34
NephroGenex, Inc. 35
NeuroVive Pharmaceutical AB 36
Noorik Biopharmaceuticals AG 37
Noxxon Pharma AG 38
Nyken B.V. 39
Orion Oyj 40
ProMetic Life Sciences Inc. 41
Quark Pharmaceuticals, Inc. 42
SBI Pharmaceuticals Co., Ltd. 43
Spherium Biomed S.L. 44
STATegics, Inc. 45
Click for Report Details @ http://www.radiantinsights.com/research/spinal-muscular-atrophy-smapipeline-review-h1-2016
About Us:
Radiant Insights Inc. is a platform for companies looking to meet their market research and business
intelligence requirements. We assist and facilitate organizations and individuals procure market
research reports, helping them in the decision making process. We have a comprehensive collection of
reports, covering over 40 key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of ancillary services such
as, research partnerships/ tie-ups and customized research solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street,
Suite 3036 San Francisco,
CA 94105 United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Website: http://www.radiantinsights.com/
Email: [email protected]
Visit our Blog: http://chemicalsandmaterialsri.blogspot.com/